ATE494906T1 - Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna - Google Patents

Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna

Info

Publication number
ATE494906T1
ATE494906T1 AT06831855T AT06831855T ATE494906T1 AT E494906 T1 ATE494906 T1 AT E494906T1 AT 06831855 T AT06831855 T AT 06831855T AT 06831855 T AT06831855 T AT 06831855T AT E494906 T1 ATE494906 T1 AT E494906T1
Authority
AT
Austria
Prior art keywords
cell
dna
cell culture
low amounts
residual
Prior art date
Application number
AT06831855T
Other languages
German (de)
English (en)
Inventor
Jens-Peter Gregersen
Holger Kost
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE494906T1 publication Critical patent/ATE494906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06831855T 2005-11-01 2006-11-01 Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna ATE494906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (1)

Publication Number Publication Date
ATE494906T1 true ATE494906T1 (de) 2011-01-15

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06831855T ATE494906T1 (de) 2005-11-01 2006-11-01 Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna

Country Status (19)

Country Link
US (2) US10655108B2 (enExample)
EP (3) EP1951296B2 (enExample)
JP (5) JP5602366B2 (enExample)
KR (1) KR20080081254A (enExample)
CN (2) CN101365480B (enExample)
AT (1) ATE494906T1 (enExample)
AU (2) AU2006310171B2 (enExample)
CA (1) CA2627971A1 (enExample)
CY (1) CY1111378T1 (enExample)
DE (1) DE602006019629D1 (enExample)
DK (1) DK1951296T4 (enExample)
EA (1) EA014062B1 (enExample)
ES (2) ES2359214T5 (enExample)
HK (1) HK1207828A1 (enExample)
NZ (1) NZ567817A (enExample)
PL (2) PL1951296T5 (enExample)
PT (1) PT2301572E (enExample)
SI (1) SI1951296T2 (enExample)
WO (1) WO2007052163A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052163A2 (en) * 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
CN101784283A (zh) * 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CA2741961A1 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
IN2012DN03418A (enExample) 2009-10-09 2015-10-23 Childrens Medical Center
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
CA2796213A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
KR102113512B1 (ko) 2010-06-01 2020-05-22 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
CN103052399B (zh) 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
JP5999817B2 (ja) * 2011-02-25 2016-10-05 ノバルティス アーゲー 外因性の内部陽性対照
SG11201401998VA (en) 2011-11-03 2014-05-29 Sentinext Therapeutics Sdn Bhd Vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
JP6054883B2 (ja) 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
JP5918870B2 (ja) 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
EP2855701A1 (en) 2012-06-04 2015-04-08 Novartis AG Improved safety testing
CA2893429A1 (en) 2012-12-03 2014-06-12 Synthetic Genomics Vaccines, Inc. Influenza virus reassortment
MX372963B (es) 2013-03-13 2020-04-01 Seqirus Uk Ltd Reordenamiento del virus de influenza b.
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
AU2014350370B2 (en) 2013-11-15 2017-04-13 Novartis Ag Removal of residual cell culture impurities
JP6774149B2 (ja) * 2014-05-28 2020-10-21 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ エンテロウイルス感染に対する免疫原としてのウイルス粒子およびその生産
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
BR112022008711A2 (pt) * 2019-11-07 2022-07-19 Seqirus Uk Ltd Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
US20240156943A1 (en) * 2021-03-30 2024-05-16 Denka Company Limited Influenza vaccine
CN115354071A (zh) * 2022-08-10 2022-11-18 上海药明生基医药科技有限公司 一种检测重组腺相关病毒宿主细胞dna残留的方法
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用
TW202516000A (zh) * 2023-07-25 2025-04-16 日商Ｋｍ生物醫藥股份有限公司 利用雞蛋培養法進行的去活化流感疫苗的製備方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
CH589453A5 (enExample) * 1974-01-14 1977-07-15 Sandoz Ag
CA1338800C (en) 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
KR20020038771A (ko) 1999-09-24 2002-05-23 장 스테판느 비내 인플루엔자 바이러스 백신
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001041814A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
EP1260581B1 (en) 2000-03-03 2010-07-07 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
WO2002087494A2 (en) 2001-04-27 2002-11-07 Glaxosmithkline Biologicals, Sa Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1499348B1 (en) 2002-04-26 2014-10-01 MedImmune, LLC Method for producing infectious influenza b virus in cell culture
WO2004056979A2 (en) 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
NZ543467A (en) * 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
EA012965B1 (ru) 2003-05-28 2010-02-26 Висконсин Эламни Рисёч Фаундэйшн Композиция для получения реассортантного рекомбинантного вируса гриппа, способ получения указанного вируса и реассортантный рекомбинантный вирус гриппа
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
PT1789084E (pt) * 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
WO2007052163A2 (en) * 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
KR101464783B1 (ko) * 2006-09-15 2014-11-26 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정

Also Published As

Publication number Publication date
EP2301572A1 (en) 2011-03-30
AU2011201968B2 (en) 2014-08-28
JP2020023557A (ja) 2020-02-13
DE602006019629D1 (de) 2011-02-24
EP2301572B1 (en) 2014-09-10
EA200801221A1 (ru) 2008-10-30
PT2301572E (pt) 2014-12-22
DK1951296T3 (da) 2011-03-28
ES2525518T3 (es) 2014-12-26
CN104474543A (zh) 2015-04-01
ES2359214T5 (es) 2014-10-08
SI1951296T1 (sl) 2011-04-29
EP2842572A1 (en) 2015-03-04
US11466257B2 (en) 2022-10-11
BRPI0618094A8 (pt) 2017-08-22
ES2359214T3 (es) 2011-05-19
CA2627971A1 (en) 2007-05-10
HK1207828A1 (en) 2016-02-12
AU2011201968A1 (en) 2011-05-19
US10655108B2 (en) 2020-05-19
JP2011256209A (ja) 2011-12-22
NZ567817A (en) 2012-01-12
SI1951296T2 (sl) 2014-09-30
KR20080081254A (ko) 2008-09-09
JP5602366B2 (ja) 2014-10-08
AU2006310171B2 (en) 2011-02-17
JP2009513694A (ja) 2009-04-02
WO2007052163A2 (en) 2007-05-10
EA014062B1 (ru) 2010-08-30
CN101365480B (zh) 2014-11-05
CN101365480A (zh) 2009-02-11
US20200377864A1 (en) 2020-12-03
JP2016185988A (ja) 2016-10-27
CY1111378T1 (el) 2015-08-05
EP1951296B1 (en) 2011-01-12
PL1951296T3 (pl) 2011-09-30
PL2301572T3 (pl) 2015-02-27
PL1951296T5 (pl) 2015-06-30
DK1951296T4 (da) 2014-09-01
HK1129837A1 (en) 2009-12-11
US20090304729A1 (en) 2009-12-10
JP7049761B2 (ja) 2022-04-07
JP2014198726A (ja) 2014-10-23
WO2007052163A3 (en) 2007-09-07
JP6639077B2 (ja) 2020-02-05
EP1951296B2 (en) 2014-07-23
BRPI0618094A2 (pt) 2011-08-16
EP1951296A2 (en) 2008-08-06
AU2006310171A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
DE602006019629D1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
EA201390538A1 (ru) Противовирусные соединения
BRPI0920240B8 (pt) composição adjuvante
WO2007024941A3 (en) Polyvalent vaccine
WO2010019262A3 (en) Polyvalent vaccine
BR112013020042A2 (pt) inibidores de vírus da hepatite c
EP4043031A3 (en) Zika viral antigen constructs
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
UA108902C2 (uk) Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
CL2011001343A1 (es) Pestivirus quimerico que comprende un virus de la diarrea viral bovina (bvdv) que expresa proteina erns de antilope; celula huesped que lo comprende; acido nucleico que lo codifica; composicion inmunogenica que comprende el pestivirus; vacuna marcadora que comprende el bvdv quimerico.
EA201170533A1 (ru) Высокодиспергируемый диоксид кремния для резин и способ его получения
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2013001285A3 (en) Fmdv vp1 peptides
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951296

Country of ref document: EP